New burn treatment cP12 enters early human safety trial
NCT ID NCT06814717
First seen Feb 22, 2026 · Last updated May 13, 2026 · Updated 9 times
Summary
This study tests a single dose of a new drug called cP12 in 6 adults who have small thermal burns (up to 10% of their body surface). The main goal is to check if the drug is safe and how the body processes it. Participants receive the drug within 2 to 24 hours after the burn and are monitored for about two weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THERMAL BURNS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Medstar Washington Hospital Center
RECRUITINGWashington D.C., District of Columbia, 20010, United States
Conditions
Explore the condition pages connected to this study.